Chapter 4 Archives • Children's Health Defense

1

Andrew J. Wakefield et al., “Ileal-Lymphoi-Nodularhyperplasia, Non-Specific Colitis, and Pervasive Developmental Disorder in Children,” The Lancet 351, no. 9103 (1998): 637-641, doi:10.1016/S0140-6736(97)11096-0.

2

Andrew J. Wakefield, Callous Regard: Autism and Vaccines-The Truth Behind a Tragedy (New York: Skyhorse Publishing, 2017), ISBN: 9781510729667.

3

Frank DeStefano et al., “Age at First Measles-Mumps-Rubella Vaccination in Children with Autism and School-Matched Control Subjects: A Population-Based Study in Metropolitan Atlanta,” Pediatrics 113, no. 2 (2004): 259-266, doi:10.1542/peds.113.2.259.

4

Frank DeStefano et al., “Age at First Measles-Mumps-Rubella Vaccination in Children with Autism and School-Matched Control Subjects: A Population-Based Study in Metropolitan Atlanta,” Pediatrics 113, no. 2 (2004): 259-266, doi:10.1542/peds.113.2.259.

5

Frank DeStefano et al., “Age at First Measles-Mumps-Rubella Vaccination in Children with Autism and School-Matched Control Subjects: A Population-Based Study in Metropolitan Atlanta,” Pediatrics 113, no. 2 (2004): 259-266, doi:10.1542/peds.113.2.259.

6

Frank DeStefano et al., “Age at First Measles-Mumps-Rubella Vaccination in Children with Autism and School-Matched Control Subjects: A Population-Based Study in Metropolitan Atlanta,” Pediatrics 113, no. 2 (2004): 259-266, doi:10.1542/peds.113.2.259.

7

Brian S. Hooker, “Reanalysis of CDC Data on Autism Incidence and Time of First MMR Vaccination,” Journal of American Physicians and Surgeons 23, no. 4 (2018): 105-109.

8

Brian S. Hooker, “Reanalysis of CDC Data on Autism Incidence and Time of First MMR Vaccination,” Journal of American Physicians and Surgeons 23, no. 4 (2018): 105-109.

9

Brian S. Hooker, “Reanalysis of CDC Data on Autism Incidence and Time of First MMR Vaccination,” Journal of American Physicians and Surgeons 23, no. 4 (2018): 105-109.

10

Brian S. Hooker, “Reanalysis of CDC Data on Autism Incidence and Time of First MMR Vaccination,” Journal of American Physicians and Surgeons 23, no. 4 (2018): 105-109.

11

Frank DeStefano et al., “Age at First Measles-Mumps-Rubella Vaccination in Children with Autism and School-Matched Control Subjects: A Population-Based Study in Metropolitan Atlanta,” Pediatrics 113, no. 2 (2004): 259-266, doi:10.1542/peds.113.2.259.

12

Nick P. Thompson et al., “Is Measles Vaccination a Risk Factor for Inflammatory Bowel Disease?,” The Lancet 345, no. 8947 (1995): 1071-1074, doi:10.1016/S0140-6736(95)90816-1.

13

Nick P. Thompson et al., “Is Measles Vaccination a Risk Factor for Inflammatory Bowel Disease?,” The Lancet 345, no. 8947 (1995): 1071-1074, doi:10.1016/S0140-6736(95)90816-1.

14

Seif O. Shaheen et al., “Measles and Atopy in Guinea-Bissau,” The Lancet 347, no. 9018 (1996): 1792-1796, doi:10.1016/s0140-6736(96)91617-7.

15

Seif O. Shaheen et al., “Measles and Atopy in Guinea-Bissau,” The Lancet 347, no. 9018 (1996): 1792-1796, doi:10.1016/s0140-6736(96)91617-7.

16

American Academy of Allergy, Asthma and Immunology, “Atopy Defined”, accessed May 17, 2023.

17

John Barthelow Classen, “Risk of Vaccine Induced Diabetes in Children with a Family History of Type 1 Diabetes,” The Open Pediatric Medicine Journal 2, (2008): 7-10, doi:10.2174/1874309900802010007.

18

John Barthelow Classen, “Risk of Vaccine Induced Diabetes in Children with a Family History of Type 1 Diabetes,” The Open Pediatric Medicine Journal 2, (2008): 7-10, doi:10.2174/1874309900802010007.

19

John Barthelow Classen, “Risk of Vaccine Induced Diabetes in Children with a Family History of Type 1 Diabetes,” The Open Pediatric Medicine Journal 2, (2008): 7-10, doi:10.2174/1874309900802010007.

20

Guillaume Pineton de Chambrun et al., “Vaccination and Risk for Developing Inflammatory Bowel Disease: A Meta-Analysis of Case-Control and Cohort Studies,” Clinical Gastroenterology and Hepatology 13, no. 8 (2015): 1405-1415 e1, doi:10.1016/j.cgh.2015.04.179.

21

Guillaume Pineton de Chambrun et al., “Vaccination and Risk for Developing Inflammatory Bowel Disease: A Meta-Analysis of Case-Control and Cohort Studies,” Clinical Gastroenterology and Hepatology 13, no. 8 (2015): 1405-1415 e1, doi:10.1016/j.cgh.2015.04.179.

22

Manish M. Patel et al., “Intussusception Risk and Health Benefits of Rotavirus Vaccination in Mexico and Brazil,” The New England Journal of Medicine 364, (2011): 2283-2292, doi:10.1056/NEJMoa1012952.

23

Manish M. Patel et al., “Intussusception Risk and Health Benefits of Rotavirus Vaccination in Mexico and Brazil,” The New England Journal of Medicine 364, (2011): 2283-2292, doi:10.1056/NEJMoa1012952.

24

Children’s Hospital of Philadelphia, “Intussusception,” accessed on April 13, 2023.

25

Medscape, “Intussusception,” accessed on April 13, 2023.

26

US Food and Drug Administration, Rotarix®: Package Insert, US License 1617 (Triangle Park, NC: GlaxoSmithKline, 2008).

27

Priya Kassin and Guy D. Eslick, “Risk of Intussusception Following Rotavirus Vaccination: An Evidence Based Meta-Analysis of Cohort and Case-Control Studies,” Vaccine 35, no. 33 (2017): 4276-4286, doi:10.1016/j.vaccine.2017.05.064.

28

Priya Kassin and Guy D. Eslick, “Risk of Intussusception Following Rotavirus Vaccination: An Evidence Based Meta-Analysis of Cohort and Case-Control Studies,” Vaccine 35, no. 33 (2017): 4276-4286, doi:10.1016/j.vaccine.2017.05.064.

29

US Food and Drug Administration, Rota Teq®: Package Insert, STN: BL125122 (Whitehouse Station, NJ: Merck & Co. Inc., 2006).

30

Children’s Hospital of Philadelphia, “Intussusception,” accessed on April 13, 2023.